Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
5.43M
-
Number of holders
-
25
-
Total 13F shares, excl. options
-
1.47M
-
Shares change
-
-424K
-
Total reported value, excl. options
-
$1.1M
-
Value change
-
-$869K
-
Put/Call ratio
-
0.02
-
Number of buys
-
11
-
Number of sells
-
-20
-
Price
-
$0.75
Significant Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q2 2022
42 filings reported holding APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share as of Q2 2022.
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) has 25 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.47M shares
of 5.43M outstanding shares and own 27% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (355K shares), RENAISSANCE TECHNOLOGIES LLC (312K shares), GEODE CAPITAL MANAGEMENT, LLC (150K shares), JANE STREET GROUP, LLC (72K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (62K shares), TWO SIGMA INVESTMENTS, LP (60.4K shares), D. E. Shaw & Co., Inc. (49.8K shares), Crestline Management, LP (48.8K shares), Tower Research Capital LLC (TRC) (47.4K shares), and BRIDGEWAY CAPITAL MANAGEMENT, LLC (45K shares).
This table shows the top 25 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.